Treating Relapsed/Refractory Multiple Myeloma With Bispecific Therapy

Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.

Expanding Bispecific Antibody Use in Community Oncology Practice

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.

CRS and ICANS Show Low Severity With Bispecifics in Multiple Myeloma

Douglas Sborov, MD, discusses adverse events in the MajesTEC-1 study of teclistamab in multiple myeloma.

Follow-Up With Teclistamab Shows Durability and Optimization of Dosing

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation of cytokine release syndrome.

Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma

During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.

Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab

During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.

Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

Teclistamab Shows Strong Efficacy in Triple-Refractory Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.

Manageable Toxicities Allow For Flexible Treatment in RRMM

In the second article of this 2-part series, Sikander Ailawadhi, MD, discusses how understanding the safety profile of the bispecific antibody teclistamab allows for physicians to treat and monitor their patients in a better way for them.

Targeting BCMA With Teclistamab Produces Impactful Results in RRMM

In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.

Teclistamab Toxicities Highly Manageable in R/R Multiple Myeloma

In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.

Physicians Share Perceptions of BCMA-Targeted Therapies for Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.

Key Factors Influence Therapeutic Choices in Penta-Refractory Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.

Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma

Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.

Managing Infections During Bispecific Therapy for Multiple Myeloma

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.

Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma

Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.